- Home
- GENC vs IPHA Comparison
GENC vs IPHA Comparison
Compare GENC & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GENC
- IPHA
- Stock Information
- Founded
- GENC 1894
- IPHA 1999
- Country
- GENC United States
- IPHA France
- Employees
- GENC N/A
- IPHA N/A
- Industry
- GENC Construction/Ag Equipment/Trucks
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- GENC Industrials
- IPHA Health Care
- Exchange
- GENC Nasdaq
- IPHA Nasdaq
- Market Cap
- GENC 181.9M
- IPHA 160.1M
- IPO Year
- GENC N/A
- IPHA 2019
- Fundamental
- Price
- GENC $13.12
- IPHA $2.38
- Analyst Decision
- GENC
- IPHA Strong Buy
- Analyst Count
- GENC 0
- IPHA 1
- Target Price
- GENC N/A
- IPHA $11.00
- AVG Volume (30 Days)
- GENC 21.9K
- IPHA 31.8K
- Earning Date
- GENC 05-16-2025
- IPHA 03-27-2025
- Dividend Yield
- GENC N/A
- IPHA N/A
- EPS Growth
- GENC 35.02
- IPHA N/A
- EPS
- GENC 1.11
- IPHA N/A
- Revenue
- GENC $113,116,000.00
- IPHA $20,831,349.00
- Revenue This Year
- GENC N/A
- IPHA $209.83
- Revenue Next Year
- GENC N/A
- IPHA $83.96
- P/E Ratio
- GENC $11.17
- IPHA N/A
- Revenue Growth
- GENC 5.44
- IPHA N/A
- 52 Week Low
- GENC $10.80
- IPHA $1.29
- 52 Week High
- GENC $24.88
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- GENC 58.45
- IPHA 71.42
- Support Level
- GENC $12.00
- IPHA $2.13
- Resistance Level
- GENC $13.59
- IPHA $2.34
- Average True Range (ATR)
- GENC 0.60
- IPHA 0.14
- MACD
- GENC 0.14
- IPHA 0.04
- Stochastic Oscillator
- GENC 82.06
- IPHA 90.07
About GENC Gencor Industries Inc.
Gencor Industries Inc and its subsidiaries is a manufacturer of heavy machinery used in the production of highway construction materials and environmental control equipment. The Company has one reporting segment, equipment for the highway construction industry. The firm's principal products include asphalt plants, combustion systems, hot mix asphalt plants, fluid heat transfer systems, and asphalt pavers.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.